BMA Fundamental Analysis - BYGGMA ASA

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to BMA. BMA was compared to 21 industry peers in the Building Products industry. BMA may be in some trouble as it scores bad on both profitability and health. BMA is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BMA has reported negative net income.

BMA had a positive operating cash flow in the past year.

BMA had positive earnings in 4 of the past 5 years.

BMA had a positive operating cash flow in each of the past 5 years.

1.2 Ratios

BMA's Return On Assets of -1.97% is on the low side compared to the rest of the industry. BMA is outperformed by 80.95% of its industry peers.

With a Return On Equity value of -6.12%, BMA is not doing good in the industry: 76.19% of the companies in the same industry are doing better.

BMA's Return On Invested Capital of 2.25% is on the low side compared to the rest of the industry. BMA is outperformed by 80.95% of its industry peers.

		Industry Rank	Sector Rank
ROA	-1.97%
ROE	-6.12%
ROIC	2.25%

ROA(3y)2.06%

ROA(5y)4.25%

ROE(3y)5.65%

ROE(5y)11.19%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BMA has a worse Operating Margin (2.90%) than 76.19% of its industry peers.

The Gross Margin of BMA (50.09%) is better than 71.43% of its industry peers.

BMA's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	2.9%
PM (TTM)	N/A
GM	50.09%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.39%

GM growth 5Y-0.63%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BMA is destroying value.

Compared to 1 year ago, BMA has about the same amount of shares outstanding.

Compared to 5 years ago, BMA has more shares outstanding

The debt/assets ratio for BMA is higher compared to a year ago.

2.2 Solvency

BMA has an Altman-Z score of 1.51. This is a bad value and indicates that BMA is not financially healthy and even has some risk of bankruptcy.

BMA has a Altman-Z score of 1.51. This is in the lower half of the industry: BMA underperforms 71.43% of its industry peers.

BMA has a Debt/Equity ratio of 1.19. This is a high value indicating a heavy dependency on external financing.

BMA has a worse Debt to Equity ratio (1.19) than 80.95% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.19
Debt/FCF	N/A
Altman-Z	1.51

ROIC/WACC0.26

WACC8.52%

2.3 Liquidity

BMA has a Current Ratio of 0.78. This is a bad value and indicates that BMA is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Current ratio value of 0.78, BMA is not doing good in the industry: 90.48% of the companies in the same industry are doing better.

A Quick Ratio of 0.44 indicates that BMA may have some problems paying its short term obligations.

The Quick ratio of BMA (0.44) is worse than 90.48% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.78
Quick Ratio	0.44

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

BMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.50%, which is quite impressive.

Looking at the last year, BMA shows a small growth in Revenue. The Revenue has grown by 6.30% in the last year.

BMA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.98% yearly.

EPS 1Y (TTM)29.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%191.48%

Revenue 1Y (TTM)6.3%

Revenue growth 3Y-2.58%

Revenue growth 5Y3.98%

Sales Q2Q%17.43%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BMA is valued a bit more expensive than the industry average as 76.19% of the companies are valued more cheaply.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	15.3

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BMA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BYGGMA ASA

OSL:BMA (6/18/2025, 7:00:00 PM)

17.6

-1.5 (-7.85%)

Chartmill FA Rating

GICS SectorIndustrials

GICS IndustryGroupCapital Goods

GICS IndustryBuilding Products

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners2.7%

Ins Owner ChangeN/A

Market Cap1.23B

AnalystsN/A

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly Dividend0

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.54
P/FCF	N/A
P/OCF	23.71
P/B	1.25
P/tB	1.28
EV/EBITDA	15.3

EPS(TTM)-0.84

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.02

FCFYN/A

OCF(TTM)0.74

OCFY4.22%

SpS32.39

BVpS14.04

TBVpS13.79

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-1.97%
ROE	-6.12%
ROCE	3.37%
ROIC	2.25%
ROICexc	2.28%
ROICexgc	2.3%
OM	2.9%
PM (TTM)	N/A
GM	50.09%
FCFM	N/A

ROA(3y)2.06%

ROA(5y)4.25%

ROE(3y)5.65%

ROE(5y)11.19%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.39%

GM growth 5Y-0.63%

F-Score6

Asset Turnover0.74

Health

		Industry Rank	Sector Rank
Debt/Equity	1.19
Debt/FCF	N/A
Debt/EBITDA	7.61
Cap/Depr	60.63%
Cap/Sales	2.35%
Interest Coverage	0.62
Cash Conversion	33.77%
Profit Quality	N/A
Current Ratio	0.78
Quick Ratio	0.44
Altman-Z	1.51

F-Score6

WACC8.52%

ROIC/WACC0.26

Cap/Depr(3y)82.97%

Cap/Depr(5y)85.75%

Cap/Sales(3y)3.16%

Cap/Sales(5y)3.26%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)29.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%191.48%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)6.3%

Revenue growth 3Y-2.58%

Revenue growth 5Y3.98%

Sales Q2Q%17.43%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y142.69%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-101.01%

FCF growth 3Y-35.16%

FCF growth 5YN/A

OCF growth 1Y-80.63%

OCF growth 3Y-28.69%

OCF growth 5Y-8.56%

BYGGMA ASA (BMA.OL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens